~~<i id='DBDE3867D1'><strike id='DBDE3867D1'><tt id='DBDE3867D1'><pre id='DBDE3867D1'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

author：Wikipedia 2025-09-29 22:46:40 - browse：114

An advisory panel to the Food and Drug Administration delivered a split decision on a surgical system used in a controversial blood pressure treatment called renal denervation.

The panel, whose advice the FDA typically follows, voted that the system developed by ReCor Medical was safe and effective. It voted that the benefits of a system developed by Medtronic, however, did not outweigh the risks.

“While this is a very safe procedure, the efficacy was mild at best,” Keith Allen, director of surgical research at St. Luke’s Hospital of Kansas City, said regarding Medtronic’s device.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： ‘Oppenheimer’ and the risks of AI in health care

hotspot

leisure time

knowledge

entertainment

knowledge

explore

MarioTama/GettyImagesTheairlineindustryisoftenheldupasamodelofoperationalexcellence—onethatthehealth

WSS

Gene editing the human germline: What are the risks?

Hyundai and Kia recall nearly 92,000 vehicles and tell owners to park them outside due to fire risk

Mega Millions pot grows to $1.25 billion after no winner

Vertex non

App could help diagnose ear infections more accurately — and at home

Baby aspirin cuts fat buildup in liver disease patients, in small study

explore

explore

hotspot

Novavax promises a turnaround & Lilly roils the obesity market

Wildfire pollution widens asthma inequities on Long Island

Supreme Court strikes down use of affirmative action

Amazon expands telehealth clinic nationwide

Novavax promises a turnaround & Lilly roils the obesity market

Adults seen as increasingly susceptible to measles

What does generative AI mean for health care? We asked experts

Nurses recount patients attacks

Heart attack and stroke risk calculators need revising

EQRx, failed developer of low

leisure time

Scientists inch closer to single

Breakthrough Alzheimer’s drugs are inaccessible in rural states

AstraZeneca to buy developer of next

Leading voice in opioid treatment defends methadone clinic system

Positive childhood experiences can help future health

CVS Caremark has created a new ploy: the drug ‘rebate credit’

knowledge

entertainment

knowledge

explore